Michelle Soriano

MICHELLE SORIANO, PhD ’07, biochemistry and molecular pharmacology, is a global biopharmaceutical executive whose career spans commercial leadership, strategy, operations, and product launches across specialty care, respiratory medicine, immunology, vaccines, and general medicines.

She is a vice president at GSK, based in Singapore, where she leads the commercial agenda for the interleukin-5 (IL-5) biologics business across GSK’s international markets. Her portfolio spans more than 25 markets in Asia-Pacific, Latin America, Canada, the Middle East, and other emerging markets. Her work includes maximizing growth of the existing portfolio, leading launches of new indications and assets, and helping shape commercial strategy and launch readiness across the broader respiratory biologics pipeline.

Before joining GSK, Soriano was executive vice president of the global respiratory franchise at Chiesi, where she led commercial strategy and operations for the company’s largest business. Based between the United States and Chiesi’s global headquarters in Parma, Italy, she led teams and business priorities across markets worldwide. She previously spent a decade at Sanofi in leadership roles across specialty care, general medicines, and vaccines, including global strategy and operations for immunology and Dupixent. Earlier in her career, she worked at McKinsey & Company and IQVIA.

Soriano’s international career has included living and working in the United States, Mexico, France, Italy, and Singapore, as well as extensive work in Japan and other global markets. She received her bachelor’s degree in biomedical research from the Universidad Nacional Autónoma de México and her PhD from Harvard University. In addition to serving on the Harvard Griffin GSAS Alumni Council, she is an honorary board member of Science Club for Girls, a nonprofit organization that fosters excitement, confidence, and literacy in STEM among girls and gender-expansive youth.